gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

New Drugs in Oncology / New Diagnosis and Modalities in Cancer Therapy

Meeting Abstract (OP430)

Inhibition of Heat-shock Protein 90 (Hsp90) with 17DMAG impairs multiple angiogenic signaling pathways in gastric cancers cells in vitro and reduces tumor growth and angiogenesis in vivo

Stöltzing O, Lang S, Klein D, Bolder U, Obed A, Gaumann A, Schlitt HJ, Geissler E
Meeting Abstract (OP431)

Novel Titanocene Anti-Cancer Drugs

Tacke M, Strohfeldt K, Pampillón C, Sweeney N
Meeting Abstract (OP432)

Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein

Krauss J, Arndt MAE, Vu BK, Martin ACR, Liu H, Newton DL, Seeber S, Rybak SM, Krauss J
Meeting Abstract (OP433)

RAB38 represents a new target antigen for immunotherapy approaches in melanoma

Jäger D, Zippelius A, Jochims C, Knuth A
Meeting Abstract (OP434)

Pharmacokinetic Study of the Humanized Anti-EGF-Receptor Monoclonal Antibody Nimotuzumab in Patients (Pts) with Locally Advanced or Metastatic Pancreatic Cancer (PC)

Hilger RA, Krauss J, Scheulen ME, Bach F, Strumberg D
Meeting Abstract (OP435)

Influence of p21 and p53 on HDAC-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo

Ocker M, Zopf S, Neureiter D, Ganslmayer M, Hahn EG, Herold C
Meeting Abstract (OP436)

Hemmung des Wachstums spontaner Magenkarzinome durch den mTOR-Inhibitior Rapamycin im transgenen Tiermodell

Schwarz B, Guba M, Schroeferl S, Ischenko I, Zimmermann W, Heeschen C, Jauch KW, Bruns CJ
Meeting Abstract (OP437)

Growth Inhibition of Solid Tumors by Intravenous Application of cG250-TNF

Bauer S, Oosterwijk E, Stenner F, Kleber S, Pfreundschuh M, Scott A, Ritter G, Old L, Renner C
Meeting Abstract (OP438)

Effective tumor therapy with coagulation active Antithrombin III in a human pancreatic cancer xenograft model in SCID mice

Celik I, Dietz C, Sürücü O, Karakas E, Kalina U, Kisker O
Meeting Abstract (OP439)

Thermotherapy using magnetic nanoparticles, a new approach in cancer therapy

Jordan A, Wust P, Maier-Hauff K, Johannsen M, Scholz R, Gneveckow U, Thiesen B, Waldöfner N, Felix R
Meeting Abstract (OP440)

Tie2/tk transfected Mesenchymal Stem Cells for a combined Stem Cell/Suicide Gene Therapy of Pancreatic Carcinoma

Conrad C, Bruns C, Niess H, Huss R, von Teichert-Lüttichau I, Mojaat A, Jauch KW, Nelson P
Meeting Abstract (OP441)

A Clinical Phase I Study of the Triple Angiokinase Inhibitor BIBF 1120 in Advanced Cancer Patients

Mross K, Frost A, Gmehling D, Bass F, Unger C, Strecker R, Hennig J, Deichsel G, Stefanic M, Stopfer P, de Rossi L
Meeting Abstract (PO442)

Enzastaurin: Correlations of Chemosensitivity and Gene Expression in Human Solid Tumors

Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke FE, Struck S, Schulz L, Blatter J, Lahn MM, Ma D, Hanauske AR
Meeting Abstract (PO443)

Pemetrexed Combined with Paclitaxel: A Phase I Trial in Advanced Solid Tumors

Graefe T, Bolling C, Lübbing C, Yilmaz E, Müller-Hagen S, Leisner B, Blatter J, Hanauske AR
Meeting Abstract (PO444)

Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy. A possible vaccine against tumors of neuroectodermal origin?

Fischer P, Krueger J, Uttenreuther-Fischer MM
Meeting Abstract (PO445)

Combined treatment of colorectal tumors with apoptosis inducing TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Additive effects in vitro and in vivo

Marini P, Kauder S, Schiller D, Denzinger S, Welz S, Jendrossek V, Budach W, Belka C
Meeting Abstract (PO446)

Antitumoral activity of the novel antitumoral compound CLU-502, isolated from Clusia rosea, in neuroblastoma and leukemia cell lines

Diaz-Carballo D, Hilger RA, Malak S, Strumberg D, Seeber S
Meeting Abstract (PO447)

Anti-angiogenesis Treatment with PTK/ZK in Ovarian Cancer: A Phase IB, Open Label, Safety and Pharmacokinetics (PK) Study of Escalating Doses of PTK787/ZK 222584 (PTK/ZK) in Combination With Paclitaxel and Carboplatin in Patients (pts) With Stage IC to IV Epithelial Ovarian Cancer

Schröder W, Abadie S, Witteveen PO, Campone M, Viens P, Jalava T, Masson E, Bilic S, Laurent D, du Bois A
Meeting Abstract (PO448)

Phase I study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumors

Lübbing C, Yilmaz E, Graefe T, Bolling C, Depenbrock H, Ohnmacht U, Müller-Hagen S, Hanauske AR
Meeting Abstract (PO449)

Syntheses of Substituted 4-(Indol-3-yl)quinazolines, a New Class of EGFR-Tyrosinkinase Inhibitors

Lüth A, Löwe W, Luger P, Weber M
Meeting Abstract (PO450)

Imaging controlled cancer therapy with magnetic nanoparticles

Alexiou C, Schick B, Jurgons R, Seliger C, Trahms L, Odenbach S, Iro H
Meeting Abstract (PO451)

Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma

Eisen T, Ahmad T, Marais R, Gibbens I, James M, Affolter A, Chao D, Bergamini L, Schwartz B, Gore ME
Meeting Abstract (PO452)

Erucylphosphocholine and erucylphosphohomocholine increase sensitivity of human malignant glioma cell lines to the cytotoxic effects of ionizing radiation

Rübel A, Handrick R, Eibl H, Budach W, Belka C, Jendrossek V
Meeting Abstract (PO453)

Enzastaurin, a Novel PKC-β Inhibitor, Inhibits Growth of Freshly Explanted Human Tumor Cells

Oberschmidt O, Eismann U, Ehnert M, Fleeth J, Lüdtke FE, Struck S, Schulz L, Blatter J, Lahn MM, Ma D, Hanauske AR
Meeting Abstract (PO454)

Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo

Michaelis M, Fichtner I, Haider W, Rothweiler F, Cinatl J, Mack A, Doerr HW, Cinatl jr. J
Meeting Abstract (PO455)

The Effect of Src Kinase Inhibition on 5-Fluorouracil Chemosensitivity Is Related to Thymidylate Synthase Expression in Human Pancreatic Carcinoma Cells

Ischenko I, Camaj P, Guba M, Brückel M, de Toni E, Graeb C, Jauch KW, Bruns C
Meeting Abstract (PO456)

Endostatin - albumin fusion protein improves in vitro and in vivo effectiveness in tumor therapy

Celik I, Dietz C, Sürücü O, Mertins P, Kisker O
Meeting Abstract (PO457)

Efficacy of CXCR2 inhibition on tumor angiogenesis in pancreatic cancer

Albrecht U, Schwarz B, Schroeferl S, Schmid G, Baumann C, Ischenko I, Guba M, Heeschen C, Jauch KW, Bruns CJ
Meeting Abstract (PO458)

Clinical phase I study of a (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH) in patients with advanced cancers

Unger C, Medinger M, Steinbild S, Drevs J, Häring B, Kratz F, Mross K
Meeting Abstract (PO459)

First patients with NF1 and malignant peripheral nerve sheath tumors treated with imantinib. Start of an open labelled phase II study

Mautner VF, Holtkamp N, Straeter R, Tatagiba M, Friedrich R, de Wit M
Meeting Abstract (PO460)

Taxol inhibits significantly an experimentally induced peritoneal carcinomatosis depending on the application mode

Hribaschek A, Meyer F, Pross M, Ridwelski K, Küster D, Lippert H
Meeting Abstract (PO461)

Bortezomib (VELCADE®, VEL) in the treatment of multiple myeloma (MM) – a prospective, non-interventional scientific study in office-based hematologists (OBH)

Knauf W, Otremba B, Overkamp F, Bammer S, Angermund R
Meeting Abstract (PE462)

The treatment of brain cancer with Drug-Nanoparticle complex

Singh S, Singh S, Bouazzaoui A, Kubasch J, Radunz HE, Sabel BA
Meeting Abstract (PE463)

Immunotherapeutic options in gastric cancer

Illert B, Meyer D, Thiede A
Meeting Abstract (PE464)

Selenium – A Novel Radiosensitizer?

Schüller P, Püttmann S, Micke O
Meeting Abstract (PE465)

Target selective activation of a TNF prodrug by urokinase type plasminogen activator (uPA) mediated proteolytic processing at the cell surface

Gerspach J, Nemeth J, Münkel S, Wajant H, Pfizenmaier K
Meeting Abstract (PE466)

Single-chain Fv immunoliposomes for drug delivery in cancer therapy

Kontermann R, Müller D, Baum P, Trunk G, Höfig I, Zettlitz K